Tufts College

Paratek Pharmaceuticals, Inc.

Other

Boston University

Hybridon, Inc.

Stuart B Levy

Mark L Nelson

Todd Bowser

Roger Frechette

Michael P Draper

Michael N Alekshun

Brent L Podlogar

Margaret Oethinger

Mohamed Y Ismail

Eric Von Hofe

Joel Berniac

Graham Jones

Beena Bhatia

Tadeusz Warchol

Kwasi Ohemeng

Mark Grier

Atul K Verma

Margret Oethinger

James F Head

Barbara A Seaton

A method for modulating RNA with tetracycline compounds is described.

Methods of using substituted tetracycline compounds to modulate RNA

Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.

Methods for treating spinal muscular atrophy using tetracycline compounds

Methods for identifying MarR family inhibiting compounds are described. The methods include the use of computer aided rational based drug design programs and three dimensional structures of MarR family polypeptides.

Methods for identifying and using MarR family polypeptide binding compounds

The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly resistant microbes. Accordingly, methods of treating infection, methods of screening for inhibitors of AcrAB-like efflux pumps, and methods of enhancing antimicrobial activity of drugs are provided. Pharmaceutical composition comprising an inhibitor of an AcrAB-like efflux pump and an antimicrobial agent are also provided.

Methods of screening for compounds that reduce microbial resistance to fluoroquinolones

Substituted tetracycline compounds, methods of synthesis, and methods of use are discussed. Tetracyclines useful for treating tetracycline related disorders are also discussed. Intermediates useful for synthesizing other tetracycline compounds are also included.

7- and 9- carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds

Methods and compositions for treatingrelated disorders in a mammal are discussed. Several novel tetracycline compounds useful for treatingrelated disorders are also included.

[object Object]

The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such asand. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.

Reducing tetracycline resistance in living cells

Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms.

Transcription factor modulating compounds and methods of use thereof

The crystal structure of the product, crystals of the MarR protein, a regulator of multiple antibiotic resistance in, and methods of crystallization of the MarR protein are described.

Crystals of MarR polypeptides, regulators of multiple antibiotic resistance

Tetracycline compounds for treatment of cryptosporidium parvum related disorders

Methods of reducing microbial resistance to drugs

Growing community of inventors

Boston, MA, United States of America

Stuart B Levy